Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

BGB 15025

  Cat. No.:  DC72741   Featured
Chemical Structure
2766481-17-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.
Cas No.: 2766481-17-6
Chemical Name: Benzamide, 4-​[5-​amino-​6-​[[1-​(1-​methyl-​4-​piperidinyl)​-​1H-​pyrazol-​4-​yl]​oxy]​-​2-​pyrazinyl]​-​N-​[2-​[(3R)​-​3-​fluoro-​1-​pyrrolidinyl]​ethyl]​-​2,​6-​dimethyl-
Synonyms: Benzamide, 4-[5-amino-6-[[1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]oxy]-2-pyrazinyl]-N-[2-[(3R)-3-fluoro-1-pyrrolidinyl]ethyl]-2,6-dimethyl-;BGB-15025
SMILES: C1CN(C)CCC1N1C=C(OC2N=C(C3=CC(C)=C(C(NCCN4CC[C@@H](F)C4)=O)C(C)=C3)C=NC=2N)C=N1
Formula: C28H37FN8O2
M.Wt: 536.64
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.
Target: HPK1
In Vitro: HPK1-IN-32 (Example A34, 0-2 μM, 2 h) inhibits pSLP76 activity in Jurkat cells with an IC50 of 65 nM [1].
References: [1]. Sanjia XU, et al. 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof. Patent. WO2022068848.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC74333 BAY-405 BAY-405 is a potent and selective MAP4K1 inhibitor with IC50 of 6 nM. BAY-405 potentiates in vitro and in vivo antitumor T-cell reactivity which overcomes the suppression by TGFβ and PGE2.
DC72741 BGB 15025 BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.
DC46921 HPK1-IN-7 HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1.
X